<p>周二，彭博社报道，皇家银行的股票研究员重申了对氙制药（Xenon Pharmaceuticals，NASDAQ：XENE）的&#34;表现优异&#34;评级。他们目前将这家生物制药公司的股票定价目标定为 55.00 美元。皇家银行的股价目标显示，相较于当前股价，潜在上涨空间为 33.24%。</p>
<p>获取 <strong>氙制药</strong> 的警报：</p>
<ul>
<li>百时美施贵宝的大举购买：在两笔生物科技交易中斥资 181 亿美元</li>
</ul>
<p>其他一些分析师最近也发布了关于 XENE 的报告。卡恩特菲茨杰拉德（Cantor Fitzgerald）重申了&#34;超重&#34;评级，并在 8 月 9 日星期五的研究报告中给出了 65.00 美元的股价目标。Wedbush 在 8 月 9 日星期五的研究报告中将氙制药的股价目标从 50.00 美元降至 49.00 美元，并给予&#34;表现优异&#34;评级。Needham &amp; Company LLC 在 8 月 12 日星期一的研究报告中将氙制药的目标股价从 62.00 美元降至 60.00 美元，并给予&#34;买入&#34;评级。最后，花旗集团在 5 月 10 日星期五的报告中将氙制药的股价目标从 62.00 美元降至 60.00 美元，并给予&#34;买入&#34;评级。一位投资分析师对该股票给予卖出评级，而九位分析师则给予该公司股票买入评级。根据 MarketBeat.com 的数据，氙制药目前的共识评级为&#34;中度买入&#34;，平均目标股价为 58.78 美元。</p>
<p><strong>阅读我们关于 XENE 的最新股票分析</strong></p>
<h2>氙制药股价上涨 2.3%</h2>
<p>周二交易日，氙制药股价上涨 0.94 美元，达到 41.28 美元。该公司的交易量为 14,893 股，相比平均交易量 395,175 股。该公司的市值为 31.3 亿美元，市盈率为-15.10，贝塔系数为 1.25。该公司的 50 天简单移动平均线为 40.29 美元，200 天简单移动平均线为 41.46 美元。氙制药的 52 周最低价为 27.99 美元，52 周最高价为 50.99 美元。</p>
<p>氙制药（Xenon Pharmaceuticals，NASDAQ：XENE）于 8 月 8 日星期四公布了季度财报。这家生物制药公司在该季度报告中每股亏损 0.75 美元，低于每股亏损 0.70 美元的共识预期。在去年同期，该公司每股盈利 0.72 美元。分析师平均预计，氙制药今年将每股亏损 3.16 美元。</p>
<h2>机构投资者对氙制药的看法</h2>
<p>一些对冲基金最近买入和卖出了该公司的股票。Parallel Advisors LLC 在第四季度将其在氙制药的持仓增加了 51.2%。Parallel Advisors LLC 现在拥有该生物制药公司的 1,125 股股票，价值 52,000 美元，较上一季度增加了 381 股。PNC 金融服务集团在第四季度购入了氙制药的新头寸，价值约 91,000 美元。17 Capital Partners LLC 在第一季度购入了氙制药的新头寸，价值约 122,000 美元。Quarry LP 在第二季度将其在氙制药的持仓增加了 207.7%。Quarry LP 现在拥有该生物制药公司的 4,000 股股票，价值 156,000 美元，较上一季度增加了 2,700 股。最后，EntryPoint Capital LLC 在第一季度购入了氙制药的新股份，价值 195,000 美元。对冲基金和其他机构投资者拥有该公司 95.45% 的股份。</p>
<h2>氙制药公司简介（获取免费报告）</h2>
<p>氙制药公司是一家总部位于加拿大的临床阶段生物制药公司，致力于开发治疗神经系统疾病患者的治疗药物。其临床开发管线包括 XEN496，一种 Kv7 钾通道开启剂，目前处于用于治疗 KCNQ2 发育性和癫痫性脑病的 III 期临床试验阶段；以及 XEN1101，一种 Kv7 钾通道开启剂，目前处于用于治疗癫痫和其他神经系统疾病的 II 期临床试验阶段。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五支股票比氙制药更好</li>
<li>什么是支撑位？</li>
<li>投资稳定性：动荡市场的前三大蓝筹股</li>
<li>什么是道·琼斯狗策略？概述和示例</li>
<li>Joby Aviation 股票：您的下一个高增长机会</li>
<li>交易停牌解释</li>
<li>不要轻视 CrowdStrike：来自 Q2 财报的关键见解</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 免费每日利润现场开放日（来自纪念碑交易联盟）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5"/></p>
<h2>您现在应该投资 1000 美元在氙制药吗？</h2>
<p>在考虑氙制药之前，您会想听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每日向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户现在购买的股票...而氙制药不在名单上。</p>
<p>尽管氙制药目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

Xenon制药

<p>加拿大皇家银行重申对 Xenon Pharmaceuticals（NASDAQ：XENE）的 “表现优异” 评级，并设定了一个价格目标，显示潜在上涨幅度为 33.24%。其他分析师也发表了看法，评级从 “买入” 到 “超配” 不等。目前，Xenon 获得了 “中等买入” 的共识评级，平均目标价为 9.78 美元。Xenon 的股价在报告当天上涨了 2.3%</p>

<p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by equities researchers at Royal Bank of Canada in a research report issued on Tuesday, Benzinga reports. They presently have a $55.00 price target on the biopharmaceutical company's stock. Royal Bank of Canada's price target points to a potential upside of 33.24% from the stock's current price.</p>
<div class="lb-trans"><p>周二，彭博社报道，皇家银行的股票研究员重申了对氙制药（Xenon Pharmaceuticals，NASDAQ：XENE）的&#34;表现优异&#34;评级。他们目前将这家生物制药公司的股票定价目标定为 55.00 美元。皇家银行的股价目标显示，相较于当前股价，潜在上涨空间为 33.24%。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><p>获取 <strong>氙制药</strong> 的警报：</p>
<ul>
<li>百时美施贵宝的大举购买：在两笔生物科技交易中斥资 181 亿美元</li>
</ul>
</div><p>A number of other analysts have also recently issued reports on XENE. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Wedbush lowered their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, August 9th. Needham &amp; Company LLC cut their target price on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, August 12th. Finally, Citigroup lowered their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $58.78.</p>
<div class="lb-trans"><p>其他一些分析师最近也发布了关于 XENE 的报告。卡恩特菲茨杰拉德（Cantor Fitzgerald）重申了&#34;超重&#34;评级，并在 8 月 9 日星期五的研究报告中给出了 65.00 美元的股价目标。Wedbush 在 8 月 9 日星期五的研究报告中将氙制药的股价目标从 50.00 美元降至 49.00 美元，并给予&#34;表现优异&#34;评级。Needham &amp; Company LLC 在 8 月 12 日星期一的研究报告中将氙制药的目标股价从 62.00 美元降至 60.00 美元，并给予&#34;买入&#34;评级。最后，花旗集团在 5 月 10 日星期五的报告中将氙制药的股价目标从 62.00 美元降至 60.00 美元，并给予&#34;买入&#34;评级。一位投资分析师对该股票给予卖出评级，而九位分析师则给予该公司股票买入评级。根据 MarketBeat.com 的数据，氙制药目前的共识评级为&#34;中度买入&#34;，平均目标股价为 58.78 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on XENE</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 XENE 的最新股票分析</strong></p>
</div><h2>Xenon Pharmaceuticals Trading Up 2.3 %</h2>
<div class="lb-trans"><h2>氙制药股价上涨 2.3%</h2>
</div><p>Xenon Pharmaceuticals stock traded up $0.94 during trading on Tuesday, reaching $41.28. The company had a trading volume of 14,893 shares, compared to its average volume of 395,175. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -15.10 and a beta of 1.25. The firm's 50-day simple moving average is $40.29 and its 200 day simple moving average is $41.46. Xenon Pharmaceuticals has a 52 week low of $27.99 and a 52 week high of $50.99.</p>
<div class="lb-trans"><p>周二交易日，氙制药股价上涨 0.94 美元，达到 41.28 美元。该公司的交易量为 14,893 股，相比平均交易量 395,175 股。该公司的市值为 31.3 亿美元，市盈率为-15.10，贝塔系数为 1.25。该公司的 50 天简单移动平均线为 40.29 美元，200 天简单移动平均线为 41.46 美元。氙制药的 52 周最低价为 27.99 美元，52 周最高价为 50.99 美元。</p>
</div><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the previous year, the company earned ($0.72) earnings per share. On average, analysts predict that Xenon Pharmaceuticals will post -3.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>氙制药（Xenon Pharmaceuticals，NASDAQ：XENE）于 8 月 8 日星期四公布了季度财报。这家生物制药公司在该季度报告中每股亏损 0.75 美元，低于每股亏损 0.70 美元的共识预期。在去年同期，该公司每股盈利 0.72 美元。分析师平均预计，氙制药今年将每股亏损 3.16 美元。</p>
</div><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对氙制药的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 51.2% during the 4th quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 381 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $91,000. 17 Capital Partners LLC bought a new position in shares of Xenon Pharmaceuticals during the 1st quarter valued at approximately $122,000. Quarry LP increased its position in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after purchasing an additional 2,700 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Xenon Pharmaceuticals during the 1st quarter valued at $195,000. Hedge funds and other institutional investors own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。Parallel Advisors LLC 在第四季度将其在氙制药的持仓增加了 51.2%。Parallel Advisors LLC 现在拥有该生物制药公司的 1,125 股股票，价值 52,000 美元，较上一季度增加了 381 股。PNC 金融服务集团在第四季度购入了氙制药的新头寸，价值约 91,000 美元。17 Capital Partners LLC 在第一季度购入了氙制药的新头寸，价值约 122,000 美元。Quarry LP 在第二季度将其在氙制药的持仓增加了 207.7%。Quarry LP 现在拥有该生物制药公司的 4,000 股股票，价值 156,000 美元，较上一季度增加了 2,700 股。最后，EntryPoint Capital LLC 在第一季度购入了氙制药的新股份，价值 195,000 美元。对冲基金和其他机构投资者拥有该公司 95.45% 的股份。</p>
</div><h2>Xenon Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>氙制药公司简介（获取免费报告）</h2>
</div><p>Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.</p>
<div class="lb-trans"><p>氙制药公司是一家总部位于加拿大的临床阶段生物制药公司，致力于开发治疗神经系统疾病患者的治疗药物。其临床开发管线包括 XEN496，一种 Kv7 钾通道开启剂，目前处于用于治疗 KCNQ2 发育性和癫痫性脑病的 III 期临床试验阶段；以及 XEN1101，一种 Kv7 钾通道开启剂，目前处于用于治疗癫痫和其他神经系统疾病的 II 期临床试验阶段。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>What is a support level?</li>
<li>Invest in Stability: Top 3 Blue-Chip Stocks for Turbulent Markets</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Joby Aviation Stock: Your Next High-Growth Opportunity</li>
<li>Trading Halts Explained</li>
<li>Don’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五支股票比氙制药更好</li>
<li>什么是支撑位？</li>
<li>投资稳定性：动荡市场的前三大蓝筹股</li>
<li>什么是道·琼斯狗策略？概述和示例</li>
<li>Joby Aviation 股票：您的下一个高增长机会</li>
<li>交易停牌解释</li>
<li>不要轻视 CrowdStrike：来自 Q2 财报的关键见解</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ FREE Daily Profits Live Open House (From Monument Traders Alliance)(Ad)</p>
<div class="lb-trans"><p>→ 免费每日利润现场开放日（来自纪念碑交易联盟）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9439&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Xenon Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1000 美元在氙制药吗？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑氙制药之前，您会想听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每日向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户现在购买的股票...而氙制药不在名单上。</p>
</div><p>While Xenon Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管氙制药目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

加拿大皇家银行重申了对 Xenon 制药（纳斯达克：XENE）的评级